CN102321170B — 利拉鲁肽变构体及其缀合物
Assigned to Hybio Pharmaceutical Co Ltd · Expires 2013-11-13 · 13y expired
What this patent protects
本发明提供一种利拉鲁肽变构体及其制备方法，利拉鲁肽变构体的氨基酸序列为：X1-Ala-Glu-X2-Thr-Phe-X3-X4-Asp-Val-X5-X6-Tyr-Leu-X7-Gly-Gln-Ala-X8-Lys(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-X9-Trp-X10-Val-Arg-Gly-Arg-X11；其中：X1为His或Cys；X2为Gly或Cys；X3为Thr或Cys；X4为Ser或Cys；X5为Ser或Cys；X6为Ser或Cys；X7为Glu或Cys；X8为Ala或删除；X9为Al…
USPTO Abstract
本发明提供一种利拉鲁肽变构体及其制备方法，利拉鲁肽变构体的氨基酸序列为：X1-Ala-Glu-X2-Thr-Phe-X3-X4-Asp-Val-X5-X6-Tyr-Leu-X7-Gly-Gln-Ala-X8-Lys(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-X9-Trp-X10-Val-Arg-Gly-Arg-X11；其中：X1为His或Cys；X2为Gly或Cys；X3为Thr或Cys；X4为Ser或Cys；X5为Ser或Cys；X6为Ser或Cys；X7为Glu或Cys；X8为Ala或删除；X9为Ala或Cys；X10为Leu或Cys或D-Ala；X11为Gly或Cys或Gly-Gly。本发明还提供一种利拉鲁肽变构体缀合物及其制备方法。本发明提供的利拉鲁肽变构体及其缀合物保留了利拉鲁肽的生物学活性，延长了半衰期，有利于患者负担的减轻。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.